UK's NICE consults on tech appraisals appeal process guide
This article was originally published in RAJ Devices
The UK's National Institute for Health and Clinical Excellence (NICE) has published a draft update of its guide to the technology appraisals appeal process, for open consultation1.
You may also be interested in...
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.